SCHEMBL5461746

SCHEMBL5461746

COc1ccc(N2C(=O)C(=Cc3ccc(O)c(O)c3)SC2=S)cc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPD1 P10809 1/20 0.70
HSPE1 P61604 1/20 0.70
HSD17B3 P37058 1/20 0.63
MEN1 O00255 8/20 0.62
KMT2A Q03164 8/20 0.62
CACNA1B Q00975 1/20 0.62
APBA1 Q02410 1/20 0.62
GRK6 P43250 1/20 0.62
DUSP26 Q9BV47 1/20 0.61
PDE4B Q07343 2/20 0.59
MAPT P10636 4/20 0.57
LMNA P02545 2/20 0.57
ALDH1A1 P00352 2/20 0.57
POLB P06746 4/20 0.55
IDE P14735 2/20 0.55
OPRK1 P41145 2/20 0.55
PSMD14 O00487 1/20 0.55
MMP2 P08253 1/20 0.55
GAA P10253 1/20 0.55
THRB P10828 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461744 1.00 HSPD1 (0.70) HSPD1HSPE1HSD17B3MEN1KMT2A
SCHEMBL5455211 0.87 HSPD1 (0.85) HSPD1HSPE1HSD17B3MEN1KMT2A
SCHEMBL5455212 0.87 HSPD1 (0.85) HSPD1HSPE1HSD17B3MEN1KMT2A
SCHEMBL17225206 0.85 DUSP26 (0.70) HSPD1HSPE1HSD17B3MEN1KMT2A
SCHEMBL13236133 0.83 HSPD1 (0.75) HSPD1HSPE1HSD17B3MEN1KMT2A
SCHEMBL5462602 0.83 HSD17B3 (0.61) HSPD1HSPE1HSD17B3MEN1KMT2A
SCHEMBL5462605 0.83 HSD17B3 (0.61) HSPD1HSPE1HSD17B3MEN1KMT2A
SCHEMBL1421361 0.81 PDE4B (0.60) HSPD1HSPE1HSD17B3MEN1KMT2A
SCHEMBL1421362 0.81 PDE4B (0.60) HSPD1HSPE1HSD17B3MEN1KMT2A
SCHEMBL1421357 0.81 PDE4B (0.60) HSPD1HSPE1HSD17B3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 HSPD1 2213/4885HSPE1 1812/4885HSD17B3 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.